Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors (TH-CR-410)
A Phase 1 Dose-Escalation Study to Determine the Safety of TH-302 in Combination With Sunitinib in Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors
Sponsor: Threshold Pharmaceuticals
A PHASE1 clinical study on Advanced Renal Cell Carcinoma and Gastrointestinal Stromal Tumors, this trial is ongoing. The trial is conducted by Threshold Pharmaceuticals and has accumulated 6 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
Jun 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Threshold Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .